Wall Street Zen Upgrades Hologic's Stock Rating to Buy

Summary

Wall Street Zen upgraded Hologic’s stock from ‘hold’ to ‘buy’. Other analysts have also given positive ratings, with target prices ranging from $68 to $90. Hologic reported a quarterly EPS of $1.08, exceeding estimates, and raised its FY 2025 EPS guidance. The stock opened at $67.29, with a market cap of $14.97 billion and a consensus rating of ‘Moderate Buy’. Institutional investors hold 94.73% of the stock, indicating strong institutional interest in the company.Market Beat

Impact Analysis

So basically, Wall Street Zen’s upgrade of Hologic to ‘buy’ is a nod to its strong financial performance and raised guidance for FY 2025. The interesting part isn’t just the upgrade itself, but the fact that institutional investors hold a whopping 94.73% of the stock, signaling strong confidence from big players Market Beat. The stock’s technicals are a mixed bag, with a long-term uptrend but a medium-term downtrend, and a MACD death cross suggesting caution . Yet, the short-term technicals are more bullish, with a MACD golden cross indicating potential for gains . The market might be underestimating the short-term upside potential here, especially given the strong institutional backing. I’d read this as a potential opportunity for short-term gains, but with a watchful eye on those medium-term technical signals.